I agree that it is highly possible Portage will invest in a conjunctive medication for chronic kidney disease patients. Cannabis derived medications for puritis and loss of appitite and other effects of chronic kidney disease could be considered. This would go well with Sentians present studies and Portage would have less restriction being out of Ontario Canada than some other US companies.
News 
Market Data 
Discover 
